Novo Nordisk to create 6000 jobs by 2022


Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. The announcement bucks the trend of recent years in pharma, which has tended to see companies downsizing drastically and closing R&D sites.

The company used its announcement to call on the Danish government to prioritise investment in research-based training in the sciences to ensure that research-driven Danish companies can continue to grow. ‘It will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,’ said the firm’s chief science officer, Mads Krogsgaard Thomsen in a statement.


Related Content

Novo Nordisk quits inflammation R&D and cuts jobs

3 September 2014 Business

news image

Firm will return to primary focus on diabetes and obesity

$100m of diabetes R&D in China

24 September 2012 Business

news image

Novo Nordisk will create 130–200 new research jobs

Most Commented

Snow soaks up pollutants from engine exhausts

14 January 2016 Research

news image

Air quality regulators should consider freezing temperatures and snow

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence